Antihypertensive effect of a new dihydropyridine calcium antagonist, PN 200-110 (isradipine), combined with pindolol.
Preliminary results of a randomized, double-blind, placebo-controlled trial of PN 200-110 (isradipine) are reported. The study involves 5 centers and 61 patients with essential hypertension. Either PN 200-110 or placebo was added to an ongoing daily regimen of 10 mg of pindolol to determine if this agent would enhance the effect of the beta-adrenoreceptor blocking agent. PN 200-110 was given twice daily, starting with a dose of 2.5 mg or 5 mg, which could be doubled after 4 weeks. The average final dose was 6.3 mg given twice daily. Supine blood pressure was significantly reduced from a mean of 162/103 mm Hg to 144/88 mm Hg (p less than 0.001) in the patients who received the combination therapy. Heart rate did not change significantly. In 3 patients therapy was withdrawn, 1 during placebo and 2 during active treatment, owing to definite or suspected side effects.
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D017275:Isradipine; D008297:Male; D008875:Middle Aged; D010069:Oxadiazoles / Q000627:therapeutic use*; D010869:Pindolol / Q000627:therapeutic use*; D011897:Random Allocation
D002121:Calcium Channel Blockers; D010069:Oxadiazoles; D010869:Pindolol; D017275:Isradipine